GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HCW Biologics Inc (NAS:HCWB) » Definitions » Institutional Ownership

HCW Biologics (HCW Biologics) Institutional Ownership : 1.22% (As of Apr. 29, 2024)


View and export this data going back to 2021. Start your Free Trial

What is HCW Biologics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, HCW Biologics's institutional ownership is 1.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, HCW Biologics's Insider Ownership is 47.26%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, HCW Biologics's Float Percentage Of Total Shares Outstanding is 57.64%.


HCW Biologics Institutional Ownership Historical Data

The historical data trend for HCW Biologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HCW Biologics Institutional Ownership Chart

HCW Biologics Historical Data

The historical data trend for HCW Biologics can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 1.76 1.79 2.17 1.70 1.27 1.27 1.28 1.29 1.23 1.22

HCW Biologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


HCW Biologics (HCW Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2929 N Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Hing C Wong director, officer: Chief Executive Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rebecca Byam officer: Chief Financial Officer C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lee Flowers officer: SVP of Business Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Rick S. Greene director C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Jin-an Jiao officer: VP of Development C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Lisa M. Giles director DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Peter Rhode officer: See Remarks C/O HCW BIOLOGICS, INC., 2929 N COMMERCE PKWY, MIRAMAR FL 33025
Medmira Capital Ltd. 10 percent owner 16F BEIKE BUILDING, 59 GAOXIN NANJIU RD, SHENZHEN F4 518057